HOME >> MEDICINE >> NEWS
Bevacizumab combined with chemotherapy prolongs survival for some patients with advanced lung cancer

Preliminary results from a large, randomized clinical trial for patients with previously untreated advanced non-squamous, non-small cell lung cancer show that those patients who received bevacizumab (AvastinTM) in combination with standard chemotherapy lived longer than patients who received the same chemotherapy without bevacizumab.

The clinical trial was sponsored by the National Cancer Institute (NCI), part of the National Institutes of Health, and conducted by a network of researchers led by the Eastern Cooperative Oncology Group. Genentech, Inc., South San Francisco, Calif., which manufactures bevacizumab, provided bevacizumab for the trial under the Cooperative Research and Development Agreement (CRADA) with NCI for the clinical development of bevacizumab.

The Data Monitoring Committee overseeing the trial (known as E4599)* recommended that the results of a recent interim analysis be made public because the study had met its primary endpoint of improving overall survival. Researchers found that patients in the study who received bevacizumab in combination with standard chemotherapy (a treatment regimen of paclitaxel and carboplatin) had a median overall survival of 12.5 months compared to patients treated with the standard chemotherapy alone, who had a median survival of 10.2 months. This difference is statistically significant. Detailed results from this trial will be presented at the American Society of Clinical Oncology Annual Meeting (ASCO) to be held in Orlando, Fla., on May 13-17, 2005.

"The exciting results of this randomized study reveal, for the first time, an improvement in survival with the addition of a targeted agent to standard chemotherapy in this patient population," said Study Chair Alan B. Sandler, M.D., of the Vanderbilt University Medical Center in Nashville, Tenn.

"This study demonstrates that mechanistic-based interventions such as angiogenesis inhibitors are making important contribution
'"/>

Contact: NCI Press Officers
ncipressofficers@mail.nih.gov
301-496-6641
NIH/National Cancer Institute
14-Mar-2005


Page: 1 2 3

Related medicine news :

1. Tuberculosis drug combined with virtual reality therapy is effective in treating fear of heights
2. Detrol LA combined with standard treatment for enlarged prostate is twice as effective
3. Nicotine more addictive when combined with other tobacco smoke chemicals, UCI study finds
4. Cognitive behavioral therapy combined with antidepressant effective in treating adolescent OCD
5. Heart disease kills more women annually than all cancers combined
6. Stents combined with clot-busting drugs effective in limiting impact of deadly form of stroke
7. Study shows people with Alzheimers can benefit from exercise combined with caregiver training
8. Wyeth chemists honored for Prevnar first combined pneumococcal vaccine for infants
9. Task force issues caution on combined hormone therapy
10. University of Pittsburgh research shows combined PET/CT finds cancerous lesions standard CT misses
11. Some patients are candidates for combined heart bypass, lung transplant surgeries

Post Your Comments:
(Date:8/1/2014)... Lake City, UT (PRWEB) August 01, 2014 ... Medical Billing Experts, LLC (MBX) with the convergence ... Medical Professionals (BOSS), Salt Lake City, UT; Premier ... Six Seven Group (67G) of Charlotte, NC. Together ... some of the nation’s largest radiology group practices, ...
(Date:8/1/2014)... (PRWEB) August 01, 2014 According to the ... is a comprehensive diet guide for women who want to ... list of protein rich foods and fat loss ... muscle mass. , Vkool writes in its review that this ... the truth about fat burning hormones and weight loss supplements. ...
(Date:8/1/2014)... The Journal of Neurosurgery is pleased ... the August issue entitled "Race Against the Clock: ... Hemorrhage." Authored by Peter Le Roux, MD, Charles ... and Alisa Schaefer, PhD, the 20-page supplement covers ... and methods in use for management of the ...
(Date:8/1/2014)... Millions of women suffer with lipedema, a ... some cases the arms, causing an abnormal accumulation of ... women in the U.S. alone are affected. With such ... embarrassment and discomfort caused by lipedema, it’s remarkable that ... that this is a disease,” says Dr. David Greuner, surgical ...
(Date:8/1/2014)... 2014 Register to join the webinar here: ... active years on record for life sciences investing. IPOs in ... 22 percent of all venture dollars spent in 2013. The ... valuations. , However, 2014 is proving more of a ... Silicon Valley Bank, while life sciences IPOs are losing steam, ...
Breaking Medicine News(10 mins):Health News:Three Market Leaders Come Together As One To Form A New Breed of Medical Billing Companies 2Health News:Three Market Leaders Come Together As One To Form A New Breed of Medical Billing Companies 3Health News:The Metabolic Switch Diet PDF Review Exposes Sally Asher's Diet Guide For Boosting Metabolism – Vkool.com 2Health News:The Metabolic Switch Diet PDF Review Exposes Sally Asher's Diet Guide For Boosting Metabolism – Vkool.com 3Health News:Management of anticoagulant-associated intracerebral hemorrhage 2Health News:Management of anticoagulant-associated intracerebral hemorrhage 3Health News:Lipedema Centers Works With Insurers To Gain Coverage For Lipedema Treatment 2Health News:Register to Join the Merrill DataSite's Webinar - Built to Sell: The Life Sciences Deal Climate 2Health News:Register to Join the Merrill DataSite's Webinar - Built to Sell: The Life Sciences Deal Climate 3
(Date:7/31/2014)... IRIDEX Corporation (Nasdaq: IRIX ) today ... ended June 28, 2014.  , Revenues were $10.6 ... $9.2 million in the 2013 second quarter and up sequentially ... for the first six months of 2014 were $20.9 million, ... of last year. , Gross margin for the quarter ...
(Date:7/31/2014)... Diabetes Care®, Inc. (NASDAQ: TNDM ), a medical ... reported its financial results for the quarter ended June 30, ... 2014 to the same period of 2013: , Sales ... , t:slim Pump shipments grew 64 percent to 2,235 pumps ... June 30, 2014 to the same period of 2013: ...
(Date:7/31/2014)... Inc. (the "Company") (Nasdaq: PCYC ) today reported ... 30, 2014. Financial Results for the Six Months ... for the quarter ended June 30, 2014 increased to $113.0 ... 2013 primarily due to IMBRUVICA ® (ibrutinib) net product ... the six months ended June 30, 2014 increased to $232.4 ...
Breaking Medicine Technology:IRIDEX Reports 2014 Second Quarter, Six-Month Results 2IRIDEX Reports 2014 Second Quarter, Six-Month Results 3IRIDEX Reports 2014 Second Quarter, Six-Month Results 4IRIDEX Reports 2014 Second Quarter, Six-Month Results 5IRIDEX Reports 2014 Second Quarter, Six-Month Results 6IRIDEX Reports 2014 Second Quarter, Six-Month Results 7Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 2Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 3Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 4Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 5Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 6Pharmacyclics Reports Second Quarter 2014 Results 2Pharmacyclics Reports Second Quarter 2014 Results 3Pharmacyclics Reports Second Quarter 2014 Results 4Pharmacyclics Reports Second Quarter 2014 Results 5Pharmacyclics Reports Second Quarter 2014 Results 6Pharmacyclics Reports Second Quarter 2014 Results 7Pharmacyclics Reports Second Quarter 2014 Results 8Pharmacyclics Reports Second Quarter 2014 Results 9Pharmacyclics Reports Second Quarter 2014 Results 10Pharmacyclics Reports Second Quarter 2014 Results 11Pharmacyclics Reports Second Quarter 2014 Results 12Pharmacyclics Reports Second Quarter 2014 Results 13Pharmacyclics Reports Second Quarter 2014 Results 14Pharmacyclics Reports Second Quarter 2014 Results 15Pharmacyclics Reports Second Quarter 2014 Results 16Pharmacyclics Reports Second Quarter 2014 Results 17Pharmacyclics Reports Second Quarter 2014 Results 18Pharmacyclics Reports Second Quarter 2014 Results 19Pharmacyclics Reports Second Quarter 2014 Results 20Pharmacyclics Reports Second Quarter 2014 Results 21Pharmacyclics Reports Second Quarter 2014 Results 22Pharmacyclics Reports Second Quarter 2014 Results 23Pharmacyclics Reports Second Quarter 2014 Results 24Pharmacyclics Reports Second Quarter 2014 Results 25
Cached News: